Dulaglutide
A once-weekly GLP-1 receptor agonist FDA-approved for type 2 diabetes, with proven cardiovascular benefits and moderate weight loss effects.
Dulaglutide, sold as Trulicity, is a once-weekly injection approved in 2014 for type 2 diabetes. Its standout evidence is the REWIND trial, still the only study of its kind to show that a GLP-1 drug cuts heart attacks and strokes in a group that mostly had no prior heart disease. It produces far less weight loss than Ozempic or Mounjaro — roughly 2–5 kg — and is not approved for weight management. Newer drugs have largely overtaken it, to the point that it is now mainly used as the yardstick they are measured against.
What is Dulaglutide?
Dulaglutide (Trulicity) is a once-weekly GLP-1 receptor agonist FDA-approved for type 2 diabetes. It consists of a GLP-1 analog fused to a modified IgG4 Fc fragment, which extends its half-life to approximately 5 days. It was the most prescribed GLP-1 agonist worldwide before semaglutide's rise. The REWIND trial demonstrated cardiovascular benefits even in patients without established cardiovascular disease, a distinction from other GLP-1 agonists.
What Dulaglutide Is Investigated For
Dulaglutide is FDA-approved for type 2 diabetes (2014) with a 2020 label expansion for cardiovascular risk reduction in T2D patients with established CV disease or multiple CV risk factors. The strongest evidence is the combined AWARD Phase 3 program (HbA1c reduction of 0.7–1.6 percentage points at 1.5 mg) and the landmark REWIND cardiovascular outcomes trial (9,901 patients, 5.4-year median follow-up) showing a 12% MACE reduction — notably in a population where only 31% had established CV disease at baseline, making it the first GLP-1 agonist with CV benefit demonstrated in a primary-prevention cohort. Renal-protection signals from the REWIND sub-analysis (15% reduction in composite renal outcome, significant reduction in new macroalbuminuria) add a meaningful secondary benefit. The SURPASS-CVOT head-to-head (NEJM 2025, PMID 41406444; n=13,165, median 4 years) established that dulaglutide 1.5 mg's CV outcome benefit is durable enough to serve as the active-comparator benchmark for newer agents — tirzepatide was non-inferior to dulaglutide for the primary composite CV outcome, while reducing major kidney events by an additional 23% (HR 0.77, p=0.0002). The honest framing is that dulaglutide produces modest weight loss (2–5 kg across approved dose range) well below semaglutide (~15%) or tirzepatide (~20%), and is not FDA-approved for weight management — its clinical position is diabetes-first with CV benefit, increasingly displaced by newer agents where weight loss, maximum glycemic effect, or kidney protection is the priority.
History & Discovery
Dulaglutide was developed by Eli Lilly as the first long-acting GLP-1 agonist to use an IgG4-Fc fusion architecture — a design choice that departed from the fatty-acid-albumin-binding approach used in liraglutide and later semaglutide. The fusion with a modified human IgG4 Fc fragment via a small peptide linker extends the half-life to approximately 5 days, enabling once-weekly dosing, while the underlying GLP-1 analog carries modifications at positions 8 and 22 for DPP-4 resistance. The FDA approved Trulicity in September 2014 for adults with type 2 diabetes, following the AWARD program of Phase III trials. The AWARD-11 trial later established efficacy and safety at higher doses (3.0 mg and 4.5 mg weekly, approved in 2020), expanding the glycemic and weight-loss effect size. The landmark REWIND cardiovascular outcomes trial (published 2019, n=9,901, median 5.4 years) demonstrated a 12% relative reduction in major adverse cardiovascular events — notably in a population where only 31% had established cardiovascular disease at baseline, making it the first GLP-1 agonist to show CV benefit in a primarily primary-prevention cohort. A 2020 FDA label expansion added reduction of MACE risk in adults with T2D and established CV disease or multiple CV risk factors. Dulaglutide has been among the most prescribed GLP-1 agonists globally but has been increasingly displaced by semaglutide and tirzepatide for both glycemic and body-weight outcomes. By 2026 the clinical positioning is well-mapped in the peer-reviewed literature — a Diabetol Int 2026 review by Samajdar and colleagues (PMID 42256584) explicitly reaffirms dulaglutide's role in contemporary cardiometabolic care, arguing it is complementary rather than superseded: REWIND remains the only GLP-1 receptor agonist trial to show a statistically significant MACE reduction in a predominantly primary-prevention population, and the fixed-dose, no-titration regimen and broad accessibility in low- and middle-income health systems are advantages the newer agents do not match. A 2026 Endocrinol Diabetes Metab network meta-analysis (PMID 42706739) pooled dose-level tirzepatide-versus-dulaglutide comparisons for HbA1c and weight, though SURPASS-CVOT alone contributed 13,165 of its 14,348 participants, so it is better read as that trial plus context than as an independent synthesis. A Clin Cardiol 2026 propensity-matched analysis of TriNetX records (PMID 42573026) documented superior cardiorenal outcomes with tirzepatide over dulaglutide in heart failure with preserved ejection fraction, and a 2026 pre-specified SURPASS-CVOT subgroup analysis (PMID 42875024) carried the question back into randomised data: among the 20.3% of participants with a history of heart failure, tirzepatide's MACE-4 benefit was more pronounced than in those without. A 2026 JACC commentary by Kaul (PMID 42233554) examines the non-inferiority design itself. The cumulative effect is that dulaglutide has become the yardstick: on 27 August 2026 the FDA approved two efficacy supplements to tirzepatide's Mounjaro application on the strength of SURPASS-CVOT, so dulaglutide's own cardiovascular evidence directly underwrote a competitor's label expansion.
How It Works
Dulaglutide mimics the GLP-1 hormone your gut naturally releases after eating. It tells your pancreas to release more insulin when blood sugar is high, slows stomach emptying so you feel full longer, and reduces appetite signals in the brain.
Dulaglutide is a fusion protein linking a GLP-1 analog (90% homology to native GLP-1, with modifications at positions 8 and 22 for DPP-4 resistance) to a modified human IgG4-Fc heavy chain via a small peptide linker. This design extends the half-life to ~5 days, enabling once-weekly dosing. It activates GLP-1R on pancreatic beta cells (glucose-dependent insulin secretion), alpha cells (glucagon suppression), gastric smooth muscle (delayed emptying), and hypothalamic neurons (appetite suppression). The REWIND trial uniquely demonstrated MACE reduction (12%) in a population where only 31% had established cardiovascular disease, suggesting primary prevention benefit.
Evidence Snapshot
Human Clinical Evidence
Extensive. AWARD trial program (10+ Phase III trials), REWIND cardiovascular outcomes trial (9,901 patients, median 5.4 years). FDA-approved since 2014.
Animal / Preclinical
Comprehensive.
Mechanistic Rationale
Very strong. Same GLP-1R mechanism as other approved GLP-1 agonists.
Research Gaps & Open Questions
What the current literature has not yet settled about Dulaglutide:
- 01Long-term cardiovascular outcomes beyond REWIND's 5.4-year median follow-up — 10-year-plus outcomes data is not yet available.
- 02Comparative effectiveness at the higher 3.0 mg and 4.5 mg doses vs semaglutide and tirzepatide — AWARD-11 established incremental benefit over the 1.5 mg dose but no head-to-head trial has compared 4.5 mg dulaglutide to 2.0 mg semaglutide. SURPASS-CVOT (NEJM 2025) compared tirzepatide to dulaglutide 1.5 mg specifically; the higher dulaglutide doses remain uncompared in CV outcomes settings.
- 03Pediatric long-term data — AWARD-PEDS provided the pediatric approval basis in 2022 but long-duration safety and growth-outcome data in adolescents are still accruing. The 2026 Diabetologia DIADEMA trial (PMID 42618811) extended the pediatric evidence base into a new adolescent population — an investigator-initiated, open-label, single-centre randomised trial of 80 adolescents aged 10–18 with transfusion-dependent thalassaemia-induced diabetes at Ain Shams University in Cairo, comparing dulaglutide 0.75 mg weekly against conventional basal-bolus insulin. This is off-label investigational use rather than a new indication, and its own authors describe the findings as exploratory.
- 04Body composition effects during weight loss — a 2026 systematic review of 60 studies and 1.25 million people (PMID 42730869) found a consistent class-wide reduction in lean body mass (SMD −0.52) but no effect on bone mineral density or fractures once the most adjusted estimates were used, and the lean-mass signal was driven mainly by liraglutide and semaglutide. Dulaglutide-specific body-composition data remain thin, and because its weight effect is smaller the clinical relevance may differ.
- 05Arrhythmia risk — a 2026 network meta-analysis of 94 trials (PMID 42933519) reported an increased atrial fibrillation risk with dulaglutide while semaglutide reduced it. The comparisons are largely indirect and the authors call for confirmation, but no dedicated arrhythmia trial exists for dulaglutide and REWIND was not designed to answer it.
- 06Dialysis and advanced kidney failure — AWARD-7 studied moderate-to-severe CKD but excluded dialysis. The only comparative data in maintenance hemodialysis is a 2026 target-trial emulation (PMID 42937520) in which dulaglutide fared worse than semaglutide on mortality and hospitalization; no randomised trial has tested dulaglutide in this population.
- 07Post-discontinuation cardiometabolic effects — REWIND and its extension were not designed as discontinuation studies, so the durability of CV benefit after stopping is not characterized.
Forms & Administration
Once-weekly subcutaneous injection via pre-filled single-dose auto-injector pen. Approved adult doses are 0.75, 1.5, 3.0 and 4.5 mg; 0.75 mg is the starting dose and 4.5 mg the maximum. In pediatric patients aged 10 and older the approved range stops at 1.5 mg. Can be administered in abdomen, thigh, or upper arm. No reconstitution or needle handling required. All injectable peptides should only be administered under the guidance of a qualified healthcare provider.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
For type 2 diabetes, the FDA-labeled starting dose is 0.75 mg once weekly; this may be escalated to 1.5 mg once weekly after at least 4 weeks if additional glycemic benefit is needed, and further to 3.0 mg and then 4.5 mg weekly at 4-week intervals based on the AWARD-11 data. The 1.5 mg dose historically served as the primary maintenance dose; 4.5 mg is the maximum approved dose.
Frequency
Once weekly by subcutaneous injection, on the same day each week, with or without regard to meals. The injection day can be shifted by up to 3 days if needed to re-establish the schedule.
Timing Considerations
Time of day
Once-weekly: same day each week. Clock time is not critical given the multi-day half-life. The approved label permits shifting the injection day by up to 3 days when needed.
Relative to meals
With or without food.
Relative to exercise
Unrelated to training.
Cycle Length
Dulaglutide is intended for indefinite chronic use in type 2 diabetes. It is not FDA-approved for weight management, though modest weight loss (3–5% of body weight on average) is a common secondary effect. Weight regain and HbA1c drift upward after discontinuation follow the same chronic-disease pattern seen across the GLP-1 class. No approved cycling protocol exists; continuation is the norm.
Protocol Notes
Dulaglutide is supplied in a pre-filled single-dose auto-injector pen with the needle hidden before and after injection — a design specifically intended to minimize needle handling and simplify administration for patients who might be hesitant with other injector formats. No reconstitution, no dose dialing, and no visible needle during injection. Injection sites are abdomen, thigh, or upper arm, with rotation recommended. The AWARD-6 head-to-head trial established dulaglutide 1.5 mg as non-inferior to liraglutide 1.8 mg for HbA1c reduction, with comparable GI tolerability. Compared to newer weekly agents (semaglutide, tirzepatide), dulaglutide produces less weight loss — which can be a clinical advantage in some T2D patients where substantial weight loss is not desired or may worsen frailty.
These doses reflect FDA-labeled protocols for type 2 diabetes. Dulaglutide is not approved for weight management. Individual dosing and continuation decisions require clinician supervision and individualized evaluation.
Timeline of Effects
Onset
HbA1c improvement begins within 2 weeks of initiation and continues to improve through week 12. Appetite suppression and modest weight loss are typically apparent within 4–8 weeks. Dulaglutide does not have a multi-step titration for tolerability (unlike semaglutide or tirzepatide), so onset of full pharmacological effect is relatively rapid — a consequence of its comparatively gentler GI profile at starting doses.
Peak Effect
In the AWARD program, HbA1c reductions of 0.7–1.6 percentage points were achieved by month 4–6 at the 1.5 mg dose and sustained through trial durations of 26–104 weeks. AWARD-11 showed incremental HbA1c reduction and weight loss with escalation to 3.0 and 4.5 mg, supporting the 2020 label expansion. Mean weight loss at 1.5 mg is typically 2–3 kg and at 4.5 mg is around 4–5 kg, well below semaglutide or tirzepatide. CV event-reduction benefit in REWIND accrued over 5+ years of continuous exposure.
After Discontinuation
Post-discontinuation data for dulaglutide parallels the GLP-1 class: HbA1c drifts toward pre-treatment baseline over weeks to months as the drug clears (half-life ~5 days, so pharmacokinetic clearance takes approximately 3–4 weeks), and whatever modest weight loss was achieved is largely regained within the following year in the absence of other interventions. CV benefits presumably reverse, though REWIND and its extension were not designed to test this specifically.
Monitoring & Measurement
Bloodwork & Labs
- •HbA1c every 3 months until stable, then twice yearly — the approved indication is glycemic control, and this is the endpoint the AWARD programme was built around.
- •Renal function (eGFR, urine albumin-to-creatinine ratio). AWARD-7 supports use in moderate-to-severe CKD, and the REWIND renal sub-analysis showed a 15% reduction in the composite renal outcome, driven largely by new macroalbuminuria.
- •Lipase and amylase only if pancreatitis is suspected; routine monitoring is not recommended and raises false positives.
- •INR after dose changes if on warfarin, and TSH if on levothyroxine, because gastric emptying is slowed.
Functional & Performance Tests
- •Body weight, recognising that 2–5 kg is the expected range rather than the double-digit percentages seen with semaglutide or tirzepatide.
- •Resting heart rate and, where there is reason for concern, pulse rhythm — a 2026 network meta-analysis raised an unconfirmed atrial fibrillation signal for this agent specifically.
When to Test
At initiation, at each dose escalation (minimum 4-week intervals), then at routine diabetes review.
Interpretation & Notes
Dulaglutide needs less monitoring scaffolding than most of its class: there is no titration schedule for tolerability, the pen delivers a fixed dose with no dialling, and ten-plus years of post-marketing data since 2014 make its interaction profile the most mature of the weekly GLP-1 agonists. The practical monitoring questions are therefore less about the drug itself than about what it is combined with — insulin and sulfonylureas need downward adjustment at initiation and at every escalation, because that is where hypoglycemia risk actually comes from.
Common Questions
Are there situations where dulaglutide is the wrong choice?
Two have been documented recently. In people on maintenance hemodialysis, a 2026 target-trial emulation of US Renal Data System records found semaglutide outperformed dulaglutide or liraglutide on both death on dialysis and hospitalization — a population the AWARD-7 kidney trial excluded entirely. And a 2026 network meta-analysis of 94 trials reported an increased risk of new-onset atrial fibrillation with dulaglutide, where semaglutide reduced it; those comparisons are largely indirect and the authors call for confirmation, but it is the only arrhythmia-specific evidence available. Neither finding overturns REWIND, and both are observational or indirect rather than randomised head-to-head.
How does dulaglutide compare to semaglutide for weight loss?
Semaglutide produces significantly greater weight loss (~15-17% vs ~3-5% for dulaglutide). However, dulaglutide has a longer track record, comes in a pre-filled auto-injector pen, and some patients tolerate it better. It's primarily positioned for diabetes rather than obesity.
Why would someone choose dulaglutide over semaglutide?
Dulaglutide's pre-filled auto-injector is simpler to use (no mixing or needle handling). Some patients experience fewer GI side effects. The REWIND trial showed CV benefits in a broader population (including those without prior CV events). Insurance coverage may also favor dulaglutide in some cases.
Does dulaglutide reduce cardiovascular risk if I don't already have heart disease?
This is dulaglutide's most distinctive evidence claim. The REWIND trial (n=9,901, median 5.4 years) showed a 12% relative reduction in major adverse cardiovascular events — and notably only 31% of participants had established cardiovascular disease at baseline. That makes dulaglutide the first GLP-1 agonist with a CV outcomes benefit demonstrated in a predominantly primary-prevention population. The 2020 FDA label expansion added MACE risk reduction in T2D adults with established CV disease or multiple CV risk factors, reflecting this finding.
What's the difference between the 1.5 mg, 3.0 mg, and 4.5 mg doses?
The 1.5 mg weekly dose was the historical maintenance dose and the one tested in REWIND. AWARD-11 established that escalating to 3.0 mg and then 4.5 mg weekly produces incremental HbA1c reduction and modest additional weight loss, leading to the 2020 FDA approval of the higher doses. Mean weight loss at 1.5 mg is typically 2–3 kg versus around 4–5 kg at 4.5 mg. The higher doses have not been tested head-to-head against semaglutide or tirzepatide in cardiovascular outcomes trials.
How does dulaglutide compare to tirzepatide for kidney protection?
The SURPASS-CVOT trial (NEJM 2025; n=13,165, median 4 years) directly compared tirzepatide to dulaglutide 1.5 mg. Tirzepatide was non-inferior for the primary composite CV outcome; in a pre-specified exploratory analysis it reduced major kidney events by a further 23% (HR 0.77, p=0.0002), with slower eGFR decline. Because that kidney result is exploratory rather than a primary endpoint, it is strong supporting evidence rather than proof — but it positions dulaglutide as an active-comparator benchmark rather than the kidney-preferred agent in T2D with established cardiovascular disease.
Who Dulaglutide Is NOT For
- •Personal or family history of medullary thyroid carcinoma (MTC) — boxed warning based on rodent C-cell tumor findings shared across the incretin class.
- •Multiple Endocrine Neoplasia syndrome type 2 (MEN2) — genetic predisposition to medullary thyroid cancer makes this an absolute contraindication per labeling.
- •Prior serious hypersensitivity reaction (anaphylaxis, angioedema) to dulaglutide or any component of the formulation — including hypersensitivity to other GLP-1 receptor agonists or to the IgG4-Fc fusion scaffold.
- •Active pancreatitis or history of recurrent pancreatitis — class-wide pancreatitis warning applies.
- •Pregnancy — animal reproductive toxicity data and absence of human pregnancy safety data make discontinuation appropriate; labeling advises stopping given long half-life.
- •Breastfeeding — transfer into human milk is not adequately characterized; risk-benefit should be individualized.
- •Severe gastroparesis or significant gastrointestinal motility disorders — delayed gastric emptying can worsen symptoms.
- •Pediatric use under age 10 — dulaglutide is approved for T2D in pediatric patients 10 and older (per AWARD-PEDS); it is not approved in younger children.
- •Concurrent use with other GLP-1 receptor agonists — redundant mechanism and amplified GI and hypoglycemia risk.
- •Severe gastrointestinal disease including inflammatory bowel disease — not an absolute contraindication but caution is advised given GI adverse event profile.
Drug & Supplement Interactions
The two principal interaction domains are hypoglycemia risk and altered oral drug absorption. Combined with insulin or insulin secretagogues (sulfonylureas, meglitinides), dulaglutide raises hypoglycemia risk materially, and downward dose adjustment of those agents at initiation and any escalation is typically required. Delayed gastric emptying may alter the rate of absorption of orally administered drugs, though dulaglutide's effect on gastric emptying is somewhat less pronounced than with daily agents or higher-exposure weekly agents — relevant monitoring applies to warfarin (INR after dose changes), levothyroxine (TSH monitoring), and narrow-therapeutic-index oral drugs. Dulaglutide has not shown clinically significant effects on oral contraceptive pharmacokinetics in dedicated studies. Concurrent use with SGLT2 inhibitors, metformin, and DPP-4 inhibitors is well-tolerated and does not require dose adjustment of dulaglutide itself. Ten-plus years of post-marketing pharmacovigilance provide a mature interaction dataset relative to the newer GLP-1 agents.
Safety Profile
Common Side Effects
Cautions
- • Thyroid C-cell tumor warning (boxed warning)
- • Pancreatitis risk
- • Gallbladder disease
- • Contraindicated in personal/family history of medullary thyroid carcinoma or MEN2
What We Don't Know
Well-characterized safety profile with extensive post-marketing data since 2014 approval.
Legal Status
United States
Dulaglutide is FDA-approved as Trulicity (September 2014) for adults with type 2 diabetes, with expanded labeling in 2020 to include reduction of MACE risk in T2D adults with established CV disease or multiple CV risk factors, and higher-dose approval (3.0 mg and 4.5 mg) based on AWARD-11. It is not approved for chronic weight management or any other obesity indication — a distinction from semaglutide, tirzepatide, and liraglutide, which all carry specific obesity-indication labels. No generic or biosimilar dulaglutide is FDA-approved as of November 2026 (Trulicity is the only dulaglutide product listed in Drugs@FDA); Eli Lilly's patent protection extends into the late 2020s. Dulaglutide injection was on FDA's drug shortage list during the GLP-1 demand surge (FDA still listed it as in shortage on February 21, 2025) but is not on FDA's current shortage list, and compounded dulaglutide is essentially unavailable through legitimate 503A pathways.
International
Dulaglutide is authorized by the EMA (Trulicity 2014), UK MHRA, Health Canada, Australia's TGA, and numerous other regulators for parallel T2D indications. Reimbursement varies by jurisdiction; it has been widely available through national formularies in Europe and Asia, though semaglutide has displaced it in many markets on efficacy grounds.
Sports & Competition
Dulaglutide is not named on the WADA Prohibited List (the 2026 list, or the 2027 list that takes effect January 1, 2027), and neither is any GLP-1 receptor agonist. Because dulaglutide is an approved medicine, WADA's S0 'non-approved substances' category does not apply, so no Therapeutic Use Exemption is needed. Athletes in weight-category sports should still check their own federation's rules before use.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Trulicity is basically the same as Ozempic — just a different brand name.
Reality
Trulicity (dulaglutide) and Ozempic (semaglutide) are distinct molecules with different structures — dulaglutide is a GLP-1–IgG4-Fc fusion, while semaglutide is a native-GLP-1-analog with a fatty diacid side chain. Clinically, semaglutide produces greater HbA1c reduction and considerably greater weight loss at its approved doses. Dulaglutide has a longer cardiovascular outcomes track record in a primary-prevention population (REWIND) and may be preferred in specific clinical contexts, but they are not interchangeable.
Myth
Dulaglutide is a good choice if you want substantial weight loss from a GLP-1.
Reality
Dulaglutide produces relatively modest weight loss — averaging 2–5 kg across approved dose range — substantially less than semaglutide (Wegovy) or tirzepatide (Zepbound). Dulaglutide is not FDA-approved for weight management and is not a clinically appropriate first-line choice if substantial weight loss is the primary goal. For patients whose primary goal is weight reduction, semaglutide or tirzepatide are the evidence-supported options.
Myth
The dulaglutide auto-injector pen means it's safer or easier than other GLP-1 agonists.
Reality
The hidden-needle auto-injector is a real usability benefit and may improve adherence for needle-averse patients. It does not alter the drug's pharmacology, side-effect profile, or clinical risk. Pen convenience is a meaningful patient-experience factor but is not a safety claim.
Myth
Dulaglutide's cardiovascular benefit shown in REWIND applies equally to all GLP-1 agonists.
Reality
REWIND's distinctive finding was CV benefit in a population where only 31% had established CV disease — suggesting primary-prevention benefit that the other major GLP-1 CVOTs (LEADER, SUSTAIN-6, SELECT) did not test directly because their populations were heavily secondary-prevention. Extrapolating dulaglutide's REWIND result to primary prevention with other GLP-1 agonists is an inference, not an established class effect. Each molecule's CVOT stands on its own.
Published Research
21 studiesTarget Trial of Semaglutide Versus Dulaglutide or Liraglutide in Patients Receiving Hemodialysis.
Diabetes Care 2026 target-trial emulation in US Renal Data System and Medicare records — the first comparative-effectiveness data in maintenance hemodialysis, a population AWARD-7 excluded. Semaglutide outperformed dulaglutide or liraglutide on death on dialysis and on hospitalization across an effective sample of 3,200 patients, making this one of the few concrete settings where dulaglutide is the weaker documented choice.
Glucagon-Like Peptide-1 Receptor Agonists and Risk of Arrhythmias: A Network Meta-Analysis.
Heart Rhythm 2026, 94 randomised trials and 155,989 patients across 12 agents. Subcutaneous semaglutide reduced new-onset atrial fibrillation versus placebo (RR 0.82), while dulaglutide was associated with an increased risk of AF and ranked near the bottom of the class (p-score 0.175 against semaglutide's 0.789). Mostly indirect comparisons, and the authors call for confirmatory work — but it is the only arrhythmia-specific synthesis naming dulaglutide.
Outcomes in patients with diabetes, atherosclerotic cardiovascular disease, and heart failure treated with tirzepatide or dulaglutide: SURPASS-CVOT analysis.
GLP-1 Receptor Agonists and Musculoskeletal Outcomes: A Systematic Literature Review and Meta-Analysis.
Efficacy and Safety of Tirzepatide Versus Dulaglutide in Type 2 Diabetes With or Without Established Atherosclerotic Cardiovascular Disease: A Network Meta-Analysis of Randomized Clinical Trials.
Dulaglutide vs insulin in adolescents with thalassaemia-induced diabetes: effect on metabolism and atherogenesis (DIADEMA).
Superior Cardiorenal Protection With Tirzepatide Over Dulaglutide in Heart Failure With Preserved Ejection Fraction: A Large-Scale Propensity Score-Matched Real-World Analysis.
Dulaglutide in the era of tirzepatide and semaglutide: reaffirming its role in contemporary cardiometabolic care.
Samajdar et al., Diabetology International 2026 — the reference paper for this page's active-comparator thesis. Argues dulaglutide is complementary rather than superseded: REWIND is still the only GLP-1 agonist trial showing significant MACE reduction in a predominantly primary-prevention population, and the fixed-dose regimen, tolerability and accessibility in low- and middle-income settings offset its weaker glycemic and weight effects.
On the Noninferiority of Tirzepatide: Insights From SURPASS-CVOT.
A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial
Pre-specified kidney analysis of SURPASS-CVOT (n=13,165, median 4.0 years) showing tirzepatide reduced the composite major kidney outcome by 23% vs dulaglutide 1.5 mg (HR 0.77, 95% CI 0.68-0.88, p=0.0002), with slower eGFR decline — positioning dulaglutide as an active-comparator benchmark rather than the kidney-preferred agent in T2D with ASCVD.
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes
Nicholls et al., NEJM 2025 — SURPASS-CVOT. The head-to-head established tirzepatide non-inferior to dulaglutide 1.5 mg for the primary composite CV outcome (12.2% vs 13.1%; HR 0.92, 95.3% CI 0.83–1.01; superiority not shown) — making dulaglutide's CV benefit the active-comparator standard against which newer dual-incretin agents are now measured.
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Landmark REWIND trial (n=9,901) demonstrating 12% reduction in MACE events with dulaglutide over median 5.4 years, notably in a population with mostly no established cardiovascular disease.
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
REWIND renal sub-analysis showing dulaglutide reduced composite renal outcome by 15%, with significant reduction in new macroalbuminuria.
Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial
Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial
Efficacy and safety of dulaglutide versus insulin glargine in patients with type 2 diabetes (AWARD-2)
Dulaglutide: an evidence-based review of its potential in the treatment of type 2 diabetes
Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial
Head-to-head comparison showing dulaglutide 1.5mg was non-inferior to liraglutide 1.8mg for HbA1c reduction, with comparable safety.
Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes (AWARD-1)
Drugs@FDA — Mounjaro (tirzepatide) NDA 215866, efficacy supplements 44 and 45 approved 27 August 2026
FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (shortage status of other GLP-1 products as of February 21, 2025)
Quick Facts
- Class
- GLP-1 Receptor Agonist
- Tier
- A
- Evidence
- Strong
- Safety
- Well-Studied
- Updated
- Nov 2026
- Citations
- 21PubMed
Also known as
Tags
Peptide Families
Related Goals
Conditions Discussed
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.